Anti-neoplastic biosimilars--the same rules as for cytotoxic generics cannot be applied.

about

Regulatory considerations in oncologic biosimilar drug development The evolving role of biosimilars in haematology-oncology: a practical perspective.Improving Access to Cancer Treatments: The Role of Biosimilars.Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations.

P2860

Q27027947-8B4B169F-BC51-4D5D-BF3E-A90D48BCD64C Q36291259-D08F6D56-20A6-4C50-8F6B-F09FA8E25173 Q47099597-BD1785F6-2FA9-4476-A555-B4CFC1441AA9 Q51034561-BF3337A1-E18B-4FAE-A706-4A2C0452CC89

P2860

Anti-neoplastic biosimilars--the same rules as for cytotoxic generics cannot be applied.

Item

http://www.wikidata.org/entity/Q44638976

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Anti-neoplastic biosimilars--the same rules as for cytotoxic generics cannot be applied.

@en

Anti-neoplastic biosimilars--the same rules as for cytotoxic generics cannot be applied.

@nl

type

Item

label

Anti-neoplastic biosimilars--the same rules as for cytotoxic generics cannot be applied.

@en

Anti-neoplastic biosimilars--the same rules as for cytotoxic generics cannot be applied.

@nl

prefLabel

Anti-neoplastic biosimilars--the same rules as for cytotoxic generics cannot be applied.

@en

Anti-neoplastic biosimilars--the same rules as for cytotoxic generics cannot be applied.

@nl

P1476

Anti-neoplastic biosimilars--the same rules as for cytotoxic generics cannot be applied.

@en

P2093

H Mellstedt

http://www.w3.org/2001/XMLSchema#string

P2860

Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusion cycle: an open-label pharmacokinetic cohort study.

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.

The regulatory framework of biosimilars in the European Union.

The safety of switching between therapeutic proteins.

Curability of advanced indolent or low-grade follicular lymphomas: time for a new paradigm?

Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration.

Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.

P304

v23-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDT325

http://www.w3.org/2001/XMLSchema#string

P478

24 Suppl 5

http://www.w3.org/2001/XMLSchema#string

P577

2013-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256200126

http://www.w3.org/2001/XMLSchema#string

P698

23975701

http://www.w3.org/2001/XMLSchema#string

P921

cytotoxicity

Anti-neoplastic biosimilars--the same rules as for cytotoxic generics cannot be applied.

about

P2860

P2860

Anti-neoplastic biosimilars--the same rules as for cytotoxic generics cannot be applied.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P921